|
|
Volumn 21, Issue 7, 2003, Pages 720-
|
|
Biotech firms jump on SARS bandwagon.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
RECOMBINANT VACCINE;
ANALYTICAL EQUIPMENT;
ARTICLE;
BIOTECHNOLOGY;
CANADA;
CHINA;
COMMERCIAL PHENOMENA;
DRUG INDUSTRY;
ECONOMICS;
EUROPEAN UNION;
FINANCIAL MANAGEMENT;
HUMAN;
METHODOLOGY;
ORGANIZATION AND MANAGEMENT;
RESEARCH;
SEVERE ACUTE RESPIRATORY SYNDROME;
UNITED STATES;
BIOTECHNOLOGY;
CANADA;
CHINA;
COMMERCE;
DRUG INDUSTRY;
EUROPEAN UNION;
FINANCING, GOVERNMENT;
HUMANS;
REAGENT KITS, DIAGNOSTIC;
RESEARCH;
SEVERE ACUTE RESPIRATORY SYNDROME;
UNITED STATES;
VACCINES, SYNTHETIC;
|
|
EID: 2142772601
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0703-720a Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
